PEA

Suspected endocannabinoid.

PPARγ

PPARγ is part of the nuclear receptor family and one of the non-GPCR cannabinoid receptors. PPARγ is involved in the regulation of fat cells/adipose tissue, insulin sensitivity and inflammation.

GPR119

GPR119 is involved in insulin secretion and its activation was shown to reduce food intake, suggesting a metabolic function.

Pain

pain is a very good target for therapeutic cannabinoids.

Parkinson's

Parkinson's Disease is a degenerative disorder of the nervous system marked by accelerated degeneration of dopamine-producing neurons in the Substantia Nigra in the brain.

Typical symptoms of Parkinson's Disease , such as (intentional) tremor, rigidity and slowness of movement are mostly ascribed to degenerating Substantia Nigra neurons.

Alzheimer's disease

Alzheimer’s disease is a chronic neurodegenerative disease and the main cause of dementia. Main common symptoms of dementia are related with memory but other cognitive processes are affected during the development of the disease.

Stroke

A stroke is marked by reduced blood flow to the brain. This reduction can be due to a blocked blood vessle (ischaemia) or a ruptured blood vessle (aneurism). Either way, as a result (part of) the brain is deprived of oxygen and nutrients which in turn causes neuronal degradation and cognitive decline.

Obesity

Energy homeostasis (balance)  is one of the primary functions of the endocannabinoid system.

Multiple Sclerosis

Multiple Sclerosis is one of the diseases where a therapeutic role for cannabinoids has been investigated for a long time.

Hypoxic-ischemic encephalopathy

Hypoxic-ischemic encephalopathy is a form of brain injury caused by oxygen deprivation during the birth process. It can cause sensorimotor and cognitive impairments including physical and intellectual disability.